• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Maggio David

    7/10/23 5:49:12 PM ET
    $NBRV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBRV alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Maggio David

    (Last) (First) (Middle)
    414 COMMERCE DRIVE
    SUITE 120

    (Street)
    WASHINGTON PA 19034

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/30/2023
    3. Issuer Name and Ticker or Trading Symbol
    Nabriva Therapeutics plc [ NBRV ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Dave Maggio 07/10/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NBRV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NBRV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NBRV
    SEC Filings

    See more
    • SEC Form 15-12G filed by Nabriva Therapeutics plc

      15-12G - Nabriva Therapeutics plc (0001641640) (Filer)

      10/25/23 1:43:51 PM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Nabriva Therapeutics plc

      EFFECT - Nabriva Therapeutics plc (0001641640) (Filer)

      10/25/23 12:15:52 AM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Nabriva Therapeutics plc

      S-8 POS - Nabriva Therapeutics plc (0001641640) (Filer)

      10/19/23 8:23:47 PM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBRV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arbutus Appoints Two New Executives

      Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Christopher Naftzger as General Counsel and Chief Compliance Officer. Mr. Naftzger succeeds Dr. Elizabeth Howard who will continue in an advisory role with respect to the on-going patent infringement l

      7/10/23 4:01:00 PM ET
      $ABUS
      $BMY
      $KRYS
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Nabriva Therapeutics Provides Corporate Update

      -Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced that, after an assessment of strategic options, its Board of Directors approved a plan to preserve cash in order to adequately fund an orderly wind down of the Company's operations. As previously disclosed, the Company engaged Torreya Capital to facilitate the exploration of a range of strategic options, including potential in-licensing or out-licensing of commercial stage assets. While the Company continues to work with Torreya Capital

      1/6/23 7:01:00 AM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

      - PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced positive topline results from their Phase 1 clinical trial that assessed the safety and pharmacokinetics (PK) of oral and intravenous (IV) XENLETA® (lefamulin) in adult patients with cystic fibrosis (CF). "We are excited to share positive topline

      11/28/22 7:01:00 AM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBRV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Hogan H Michael Iii

      3 - Nabriva Therapeutics plc (0001641640) (Issuer)

      7/10/23 5:51:57 PM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Maggio David

      3 - Nabriva Therapeutics plc (0001641640) (Issuer)

      7/10/23 5:49:12 PM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Gelone Steven P. covered exercise/tax liability with 140 units of Ordinary Shares, decreasing direct ownership by 0.97% to 14,283 units to cover taxes

      4 - Nabriva Therapeutics plc (0001641640) (Issuer)

      1/31/23 8:56:21 PM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBRV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Northland Securities reiterated coverage on Nabriva Therapeutics with a new price target

      Northland Securities reiterated coverage of Nabriva Therapeutics with a rating of Outperform and set a new price target of $6.00 from $9.00 previously

      3/12/21 8:13:45 AM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBRV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Nabriva Therapeutics plc (Amendment)

      SC 13G/A - Nabriva Therapeutics plc (0001641640) (Subject)

      2/9/22 9:22:48 AM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Nabriva Therapeutics plc

      SC 13G - Nabriva Therapeutics plc (0001641640) (Subject)

      11/19/21 12:57:43 PM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Nabriva Therapeutics plc (0001641640) (Subject)

      2/8/21 10:35:31 AM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBRV
    Leadership Updates

    Live Leadership Updates

    See more
    • Arbutus Appoints Two New Executives

      Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Christopher Naftzger as General Counsel and Chief Compliance Officer. Mr. Naftzger succeeds Dr. Elizabeth Howard who will continue in an advisory role with respect to the on-going patent infringement l

      7/10/23 4:01:00 PM ET
      $ABUS
      $BMY
      $KRYS
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer

      DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the appointment of Dr. Christine Guico-Pabia, M.D., MBA, MPH as Chief Medical Officer (CMO) effective October 1, 2021. "We are very pleased to have Christine join our senior leadership team. Christine brings a well-rounded profile to the CMO role, with extensive experience across several therapeutic areas from clinical development through to the post-marketing support of multiple commercial stage products over the course of h

      10/1/21 7:01:00 AM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer

      DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the appointment of Daniel Dolan as Chief Financial Officer (CFO), effective close of business March 12, 2021. Mr. Dolan will replace current CFO Gary Sender, who is retiring from Nabriva. Mr. Sender will serve as a consultant for Nabriva at least through the remainder of 2021 to support Mr. Dolan’s transition into the CFO role. “We are very pleased to have Dan join our leadership team. Dan is a seasoned business le

      2/26/21 8:00:00 AM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBRV
    Financials

    Live finance-specific insights

    See more
    • Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update

      - Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced it has pivoted its strategic focus towards commercialization efforts, primarily focused on SIVEXTRO, to extend its cash runway, while exploring strategic options. Nabriva also issued financial results for the t

      11/10/22 4:01:00 PM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022

      DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. The dial-in number for the conference call is 833-634-2311 for domestic participants and 412-902-4177 for international p

      11/7/22 7:01:00 AM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split

      DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) --  Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 16, 2022. At the Annual General Meeting of Shareholders on August 11, 2022, Nabriva Therapeutics' shareholders approved, subject to and conditional upon the Board of Directors of Nabriva Therapeutics determining,

      9/15/22 7:01:00 AM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care